Neurogene Inc. (NGNE)
NASDAQ: NGNE
· Real-Time Price · USD
17.25
0.40 (2.37%)
At close: Sep 24, 2025, 3:59 PM
17.25
0.00%
Pre-market: Sep 25, 2025, 07:36 AM EDT
2.37% (1D)
| Bid | 16.48 |
| Market Cap | 246.19M |
| Revenue (ttm) | -925K |
| Net Income (ttm) | -84.39M |
| EPS (ttm) | -4.31 |
| PE Ratio (ttm) | -4 |
| Forward PE | -3.01 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 17.59 |
| Volume | 127,219 |
| Avg. Volume (20D) | 160,742 |
| Open | 16.94 |
| Previous Close | 16.85 |
| Day's Range | 16.94 - 17.52 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.58 |
| Ex-Dividend Date | n/a |
About NGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+28.36%
Neurogene shares are trading higher after the comp...
Unlock content with
Pro Subscription
4 months ago
-7.12%
Neurogene shares are trading lower after Baird downgraded the stock from Outperform to Neutral and cut its price target from $38 to $24.
2 weeks ago · businesswire.com
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
